Denmark· DK-28107209924
Clonidinhydrochlorid "Orifarm"
A clonidine product containing clonidinhydrochlorid, registered in Denmark by Orifarm A/S. The same ATC class is registered in 13 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Clonidine is registered in 13 of 19 countries.
Countries holding a registration under ATC C02AC01 (clonidine), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 8 of them publish a price we can compare per daily dose
Clonidine · ATC C02AC01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of clonidine costs, country by country.
Normalised to the WHO defined daily dose (0.45 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Clonidine · price per daily dose (0.45 mg)
USD · FX 28 Sept 2026
- US United States$0.074 (acquisition cost)
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- CLONIDINHYDROCHLORID
- Manufacturer
- Orifarm A/S
- Country
- Denmark (DK)
- ATC code
- C02AC01
- ATC class
- Clonidine
- Defined daily dose
- 0.45 mg, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28107209924
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
307 interactions on record for clonidine.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Clonidine · interactions on record
307 records
- 2 severe
- 127 moderate
- 2 minor
- 175 info
Most severe, free to view
- DoxepinD04AX01severe
- DoxepinN06AA12severe
- MetoclopramideA03FA01moderate
- ThiethylperazinA04AB03moderate
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under C02AC01
Clonidine, as other registers publish it.
- FinlandCaprysinSchering Oy
- FinlandCaprysinSchering Oy
- NorwayCaruxinMacure Pharma ApS
- DenmarkCaruxinMacure Pharma ApS
- IrelandCatapres Ampoules 150 micrograms in 1 ml Solution for InjectionGlenwood GmbH
- IrelandCatapres Tablets 100 microgramsGlenwood GmbH
- NorwayCatapres-TTS-2Boehringer Ingelheim
- FinlandCatapresanGlenwood GmbH Pharmazeutische Erzeugnisse
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d9af6228-2103-486d-8215-d6b0e659ac4f GET /v1/drugs/d9af6228-2103-486d-8215-d6b0e659ac4f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "injektionsvæske, opløsning",
"source": "dkma",
"strength": "150 mikrogram/ml",
"auth_role": "DKMA",
"dk_drugid": "28107209924",
"substance": "CLONIDINHYDROCHLORID",
"auth_procedure": "Par-Imp",
"in_medicinpriser": false,
"registration_date_serial": "45554"
}See everything about clonidine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.